To view this email as a web page, click here.

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

COMPOUNDING

TODAY'S HEADLINES

Debunking common misconceptions about IV automation

By John Barickman, RPh, MBA, FACHE
The misconceptions of IV robotics are many, but there are also many real-world examples of how hospitals and health systems are improving processes by implementing technology to support in-house sterile compounding. Read more

Buccal buprenorphine approved for patients with chronic pain

by Erin Bastick
Belbuca, for patients with chronic pain, is expected to be available in the United States during the first quarter of 2016. Read more

CONTINUING EDUCATION

November 2015
Recognition of drug-induced pulmonary disease and management of idiopathic pulmonary fibrosis

Session code: 15DT36-KXF58

This month's CE activity is part of the CPE series, "Medication Therapy Management for the Patient with Respiratory Disease." From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this activity is to review the common medications associated with pulmonary toxicity and to review how to recognize and treat idiopathic pulmonary fibrosis.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT36-KXF58.
Copy the session code — 15DT36-KXF58  — before logging into the Online CE Center. When the page for the Online CE Center opens, paste the session code into the appropriate field, under your NABP ID.

EDITOR'S PICK

Doctors understand patients' IPF concerns

by Christine Blank
A new survey of more than 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis (IPF) negatively impacts patients. Details

November 13, 2015

Related Articles

[BLOG]: A better IV compounding strategy: Leveraging in-house advantage

[BLOG]: Pain management: Can we balance patient access, safety and economic value?

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News

Click to contact the editorial team. Click to contact the sales team.

Part of the

ModernMedicine logo

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply.
Please use the links provided if you have questions or concerns regarding this email or your subscription.

This email was sent by: %%Member_Busname%%
%%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%

 

NEWSLETTER

Forward to a Friend
Privacy Statement
Terms of Service
Update Profile
Add/Remove Newsletters
Contact Us